Physician profile
Eric D Whitman
NPI 1609840636
$847,529.74
in general payments reported to CMS, 2019-2025
51 companies · $72K in 2025
The $72K reported for 2025 was more than what 99% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269K · 2020: $105K · 2021: $90K · 2022: $132K · 2023: $108K · 2024: $70K · 2025: $72K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $168K · Consulting Fee: $46K · Travel and Lodging: $29K · Food and Beverage: $7,909.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $168,116.60 |
| Consulting Fee | $45,903.00 |
| Travel and Lodging | $28,891.87 |
| Food and Beverage | $7,909.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $492,328.45 | 2019-2025 | Opdivo, Opdualag |
| Regeneron Healthcare Solutions, INC. | $131,290.14 | 2019-2025 | Libtayo |
| Genzyme Corporation | $109,944.18 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $79,201.08 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Regeneron Pharmaceuticals, INC. | $11,594.03 | 2022-2023 | Libtayo |
| Sun Pharmaceutical Industries INC. | $11,363.54 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $3,040.20 | 2019-2025 | |
| Array Biopharma INC | $2,600.05 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Eisai Co., Ltd. | $1,875.00 | 2020 | |
| Celgene Corporation | $796.81 | 2020-2025 | Reblozyl, Pomalyst, Opdualag |
| Boehringer Ingelheim Pharmaceuticals, INC. | $671.04 | 2021-2023 | |
| Daiichi Sankyo INC. | $529.29 | 2022-2025 | Enhertu |
| Seagen INC. | $280.17 | 2020-2023 | Tukysa |
| Mirati Therapeutics, INC. | $233.83 | 2023-2024 | Krazati |
| Pfizer INC. | $215.56 | 2023-2025 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mevion_medical_systems_inc | $209.41 | 2023 | Pts250 |
| Genentech USA, INC. | $153.14 | 2019-2021 | |
| Eisai INC. | $133.66 | 2020-2024 | |
| Janssen Biotech, INC. | $112.83 | 2020-2025 | Darzalex, Talvey, Tecvayli |
| Amgen INC. | $108.94 | 2019-2021 | |
| Glaxosmithkline, LLC. | $98.84 | 2022-2023 | Zejula, Jemperli |
| Karyopharm Therapeutics INC. | $94.27 | 2022-2023 | Xpovio |
| Astrazeneca Pharmaceuticals Lp | $87.66 | 2019-2025 | Calquence, Lynparza |
| Astellas Pharma US INC | $79.24 | 2020-2023 | Xospata |
| Kerecis Limited | $59.35 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Incyte Corporation | $57.44 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $42.22 | 2022 | |
| Acera Surgical, INC. | $36.86 | 2023 | Restrata Wound Matrix |
| Takeda Pharmaceuticals U.S.A., INC. | $31.81 | 2022-2024 | Fruzaqla |
| Pharmacyclics LLC, An Abbvie Company | $29.55 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $29.11 | 2020 | |
| Foundation Medicine, INC. | $28.33 | 2023 | |
| Gilead Sciences, INC. | $19.56 | 2025 | Trodelvy |
| Cumberland Pharmaceuticals, INC. | $19.00 | 2025 | Sancuso |
| Alexion Pharmaceuticals, INC. | $16.96 | 2024 | Ultomiris |
| Abbvie INC. | $16.76 | 2022 | |
| Galvanize Therapeutics, INC | $15.76 | 2024 | Aliya System |
| Genmab U.S., INC. | $15.65 | 2022 | |
| Acceleron Pharma, INC. | $14.76 | 2021 | |
| Eusa Pharma (US) LLC | $13.96 | 2019 | |
| Exelixis INC. | $13.92 | 2021 | |
| Tersera Therapeutics LLC | $13.78 | 2022 | |
| Sanofi-Aventis U.S. LLC | $13.60 | 2021 |
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Whitman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.